Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Protein Page:
MFSD8 (human)

Overview
MFSD8 May be a carrier that transport small solutes by using chemiosmotic ion gradients (Potential). Defects in MFSD8 are the cause of neuronal ceroid lipofuscinosis type 7 (CLN7). A form of late infantile neuronal ceroid lipofuscinosis. CNL are a clinically and genetically heterogeneous group of neurodegenerative disorders characterized by the intracellular accumulation of autofluorescent lipopigment storage material in different patterns ultrastructurally. The patterns most often observed CLN7 are mixed combinations of granular, curvilinear, fingerprint, and rectilinear profiles. The clinical course includes progressive dementia, seizures, and progressive visual failure. Belongs to the major facilitator superfamily. Note: This description may include information from UniProtKB.
Protein type: Membrane protein, integral; Membrane protein, multi-pass
Cellular Component: lysosomal membrane; integral to membrane
Biological Process: cell death; transmembrane transport
Reference #:  Q8NHS3 (UniProtKB)
Alt. Names/Synonyms: Ceroid-lipofuscinosis neuronal protein 7; ceroid-lipofuscinosis, neuronal 7, late infantile; CLN7; major facilitator superfamily domain containing 8; Major facilitator superfamily domain-containing protein 8; MFSD8; MGC33302
Gene Symbols: MFSD8
Molecular weight: 57,628 Da
Basal Isoelectric point: 6.41  Predict pI for various phosphorylation states
Select Structure to View Below

MFSD8

Protein Structure Not Found.


STRING  |  Scansite  |  Phospho.ELM  |  Pfam  |  DISEASE  |  Source  |  GeneCards  |  UniProtKB  |  Entrez-Gene  |  GenPept  |  Ensembl Gene


Modification Sites and Domains  

Modification Sites in Parent Protein, Orthologs, and Isoforms  
 

Show Multiple Sequence Alignment


 SS 

SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.


 MS 

MS: The number of records in which this modification site was assigned using ONLY proteomic discovery-mode mass spectrometry.


       human

 
0 2 T17 QEPLLGDTPGSREWD
  mouse

 
S18-p EPLLGPGsPGSREWS
Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.